This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients will continue to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01673919?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
